Premium
Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis
Author(s) -
Wolfe Gil I.,
Barohn Richard J.,
Foster Barbara M.,
Jackson Carlayne E.,
Kissel John T.,
Day John W.,
Thornton Charles A.,
Nations Sharon P.,
Bryan Wilson W.,
Amato Anthony A.,
Freimer Miriam L.,
Parry Gareth J.
Publication year - 2002
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.10224
Subject(s) - myasthenia gravis , medicine , placebo , randomized controlled trial , antibody , open label , anesthesia , immunology , pathology , alternative medicine
We initiated a randomized, double‐blinded, placebo‐controlled trial of intravenous immunoglobulin (IVIG) treatment in myasthenia gravis (MG). Patients received IVIG 2 gm/kg at induction and 1 gm/kg after 3 weeks vs. 5% albumin placebo. The primary efficacy measurement was the change in the quantitative MG Score (QMG) at day 42. Fifteen patients were enrolled (6 to IVIG; 9 to placebo) before the study was terminated because of insufficient IVIG inventories. At day 42, there was no significant difference in primary or secondary outcome measurements between the two groups. In a subsequent 6‐week open‐label study of IVIG, positive trends were observed. © 2002 Wiley Periodicals, Inc. Muscle Nerve 26: 549–552, 2002